Anuh Pharma Ltd.: Navigating Growth with Operational Excellence and Strategic Vision

Anuh Pharma Ltd., a significant player in the bulk drug manufacturing sector, recently unveiled its investor presentation for Q3 FY26, offering a detailed look into its financial performance and strategic direction. The company reported a robust Q3 FY26, with operating revenue sustaining strong momentum at ₹201 crore, a notable increase from ₹186 crore in the preceding quarter. This performance underscores the company's sustained emphasis on operational excellence, strong compliance standards, and proactive business expansion, all contributing to improved performance and long-term value creation.

For the nine-month period ending December 31, 2025 (9M FY26), Anuh Pharma's operating revenue reached ₹569.54 crore, marking a substantial 22.91% year-on-year growth compared to ₹463.38 crore in 9M FY25. This growth was primarily fueled by capacity enhancement and a stronger product mix. The company's operating profit for 9M FY26 stood at ₹109.26 crore, a 5.32% increase from ₹103.74 crore in the previous year. However, EBITDA for 9M FY26 saw a slight decrease of 5.66% year-on-year, coming in at ₹47.45 crore compared to ₹50.29 crore in 9M FY25. Similarly, Profit Before Tax (PBT) and Profit After Tax (PAT) also experienced year-on-year declines for the nine-month period, decreasing by 11.49% and 15.85% respectively. Despite these moderations, management highlighted that margins are on a recovery path, driven by improved realizations, cost optimization, and operating leverage benefits.

Operational Excellence and Strategic Initiatives

Anuh Pharma's commitment to operational excellence is evident in its continuous investments and compliance achievements. The company successfully completed a USFDA inspection in February 2026 with zero Form 483 observations, a testament to its robust quality systems. Over the past five years, significant investments in capacity expansion and throughput optimization have led to improved asset utilization and enhanced operational efficiency. The company's manufacturing facility at Tarapur now boasts a total output capacity of 2400 MTPA, spread across 11,400 sq. meters with 9 API blocks and 2 intermediate blocks.

Sustainability is another core focus, with investments in solar energy infrastructure aimed at lowering power costs and enhancing environmental responsibility. Furthermore, the commissioning of a Zero Liquid Discharge (ZLD) system ensures 100% treatment of generated pollution, providing a significant compliance advantage. The company's R&D facility at Mahape, spanning over 10,000 sq.ft., is dedicated to developing new products and processes, particularly focusing on complex chemistry products and lifestyle drugs for conditions like diabetes, hypertension, and obesity. This strategic pipeline includes products such as Linagliptin, Empagliflozin, and Bedaquiline Fumarate, positioning Anuh Pharma for future market penetration.

Market Presence and Product Mix

Anuh Pharma maintains a strong market presence with marketing partnerships across 59 countries, including Europe, Mexico, and South Africa. Exports contributed approximately 55% of its revenues in FY24-25, highlighting its global reach. The company is a leading manufacturer of Macrolides and Anti-TB products in India, alongside being a major player in Anti-bacterials, Anti-malarial, Anti-hypertension, and Corticosteroids.

In terms of product mix revenue contribution for 9M FY26, Erythromycin salts remain the largest contributor at ₹172 crore, followed by Cortico Steroids at ₹76 crore and Higher Macrolides at ₹73 crore. This diversified product portfolio, coupled with a strong customer base, provides a stable revenue foundation.

Future Outlook and Investor Confidence

Looking ahead, Anuh Pharma anticipates a steady growth rate of 15-16% per annum. The company's growth strategy is anchored in market expansion, the introduction of new products, and the pursuit of selective inorganic growth opportunities. Management expects the year to conclude as per budget estimates, driven by a good order position and improving pricing trends in key molecules. Capacity expansion, higher utilization, and continued operational efficiencies are projected to drive sustainable margin improvement in the upcoming quarters.

Anuh Pharma's disciplined capital allocation, strong R&D capabilities, and unwavering commitment to quality and compliance instill confidence. The company's proactive approach to market trends and product development, particularly in high-demand therapeutic areas, positions it for sustained growth and value creation for its stakeholders.